Currier/ 2001/rater blinded | Risperidone 2 mg po plus lorazepam 2 mg po/ haloperidol 5 mg im plus lorazepam 2 mg im | 62 | 71 | | | 30 | 30 | | | % Improvement in PANSS according to baseline | 60 minutes | 0 | 3 | | | No significant difference between the two treatment groups | ED/24 hours |
Brook/ 2000/ random | Ziprasidone 10 mg im/ haloperidol 2.5–10 mg im | 13 | 7 | | | 83 | 40 | | | % Improvement in BPRS according to baseline | 72 hours | 0 | 21.4 | | | Ziprasidone is significantly more effective and better tolerated | Inpatient/ 72 hours |
Jones/ 2001* / DBR | Olanzapine 10 mg im/ haloperidol 7.5 mg im/ placebo im | 27 | Not stated | Not stated | | 122 | 116 | 47 | | % Improvement in BPRS positive subscale according to baseline | 2 hours | Not stated | Not stated | Not stated | | Olanzapine and haloperidol are superior to placebo but not significantly differ from each other | Inpatient/ 24 hours |
Wright/ 2001* / DBR | Olanzapine 10 mg im/ haloperidol 7.5 mg im/ placebo im | 73 | 69 | 33 | | 131 | 126 | 54 | | Improvement of at least 40% in excited component of PANSS | 2 hours | 0.8 | 5.6 | Not stated | | Olanzapine is not inferior to haloperidol in efficacy; has a significantly more rapid onset of action | Inpatient/ 24 hours |
Meehan/ 2001/DBR. | Olanzapine 10 mg im/ lorazepam 2 mg im / placebo im | 74 | | 38 | 54 | 98 | | 50 | 51 | % Improvement in excited component of PANSS according to baseline | 2 hours | No significant difference in EPS side effects | Olanzapine is superior to placebo and lorazepam in reducing agitation | Not stated/ 24 hours |
Yildiz/ 2003†/ observ | Risperidone 1–2 mg po ± lorazepam 1 mg po/ haloperidol 2–5 mg im or po ± lorazepam 1–2 mg im or po | 57 | 41 | | | 8 | 10 | | | % Improvement in BPRS according to baseline | 2 hours | 0 | 0 | | | Risperidone is not inferior to haloperidol in efficacy | ED/2 hours |